Related Experiment Video
Updated: Jul 11, 2025
Fetal Echocardiography and Pulsed-wave Doppler Ultrasound in a Rabbit Model of Intrauterine Growth Restriction
Published on: June 29, 2013
Biomarkers for Diagnosing and Treating Fetal Growth Restriction
Mengyao Wu1, Junyu He2, Yetao Chen1
1Hubei Key Laboratory of Natural Products Research and Development, Yichang Key Laboratory of Development and Utilization of Health Products with Drug and Food Homology, College of Biology Pharmacy, China Three Gorges University, Yichang, 443002, China.
Insights
Early prediction of fetal growth restriction (FGR) is crucial. This review highlights novel biomarkers for diagnosing FGR, improving fetal health outcomes and informing future treatments.
Area of Science:
- Obstetrics and Gynecology
- Perinatology
- Biomarker Research
Background:
- Fetal growth restriction (FGR) is a significant obstetric complication associated with increased risks of fetal and neonatal death.
- FGR-affected fetuses face long-term risks including cognitive deficits and adult-onset diseases.
- Current methods for early FGR risk determination are limited, with few reliable predictive indicators.
Purpose of the Study:
- To review current strategies for the prediction and diagnosis of FGR.
- To explore the significance of various biomarkers in FGR assessment.
- To provide insights into potential new diagnostic and therapeutic approaches for FGR.
Main Methods:
- Literature review focusing on FGR prediction, diagnosis, and biomarkers.
- Analysis of biomarkers related to gene regulation, apoptosis, mitochondrial function, and inflammation.
- Synthesis of research findings on the clinical utility of identified biomarkers.
Main Results:
- Several novel biomarkers show promise for early FGR prediction and diagnosis.
- Biomarkers associated with genetic regulation, cellular death pathways, mitochondrial dysfunction, and inflammation are key areas of investigation.
- Despite being in early research stages, these biomarkers offer valuable insights into fetal health threats.
Conclusions:
- Emerging biomarkers hold significant potential for improving the early detection and management of FGR.
- Further research into these biomarkers could lead to enhanced fetal surveillance and personalized interventions.
- These findings pave the way for novel therapeutic strategies to mitigate the adverse outcomes of FGR.
Abstract:
Fetal growth restriction (FGR), a common obstetric complication, significantly increases the risks of fetal intrauterine death and neonatal death, and fetuses with growth restriction are prone to cognitive retardation and various diseases in adulthood. The early determination of FGR risk is contentious in clinical research, and few indicators are available for the early prediction and diagnosis of FGR. This review focuses on the prediction and diagnosis of FGR, as well as the significance of biomarkers for FGR, such as those related to gene regulation, apoptosis, mitochondrial function, and inflammation. Although many of these biomarkers are still in the early stages of research, they are good predictors of the threats to fetal health and safety, and they provide new insights for the treatment of FGR.
